SCHEMBL10293142

SCHEMBL10293142

Cc1c(C(=O)NC2CC2)oc2ccc(S(=O)(=O)Nc3ccccn3)cc12

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
NPC1 O15118 7/20 0.53
RAB9A P51151 7/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
CNR1 P21554 2/20 0.52
CNR2 P34972 2/20 0.52
TP53 P04637 1/20 0.50
ATM Q13315 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 1/20 0.49
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MCHR1 Q99705 1/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293099 0.89 TDP1 (0.64) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL1156495 0.85 TDP1 (0.64) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL1156370 0.83 TDP1 (0.62) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL8276806 0.82 TDP1 (0.58) TDP1NPC1RAB9AKMT2ACNR1
SCHEMBL10293106 0.82 TDP1 (0.58) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL10259648 0.81 TDP1 (0.65) TDP1NPC1RAB9AKMT2ACNR1
SCHEMBL10293169 0.81 TDP1 (0.64) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL10293201 0.81 TDP1 (0.59) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL8276951 0.80 NPC1 (0.64) TDP1NPC1RAB9AKMT2ACNR1
SCHEMBL8277464 0.80 NPC1 (0.62) TDP1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C TDP1 4014/4885NPC1 1567/4885RAB9A 1541/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C TDP1 4014/4885NPC1 1567/4885RAB9A 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.